Literature DB >> 15708941

Psoriasis assessment tools in clinical trials.

S R Feldman1, G G Krueger.   

Abstract

In clinical practice, broad global assessments of psoriasis disease activity and its effect on patients' quality of life are used to assess the severity of patients' disease and their response to treatment. In clinical trials, more objective, validated instruments are required. Several such instruments have been developed and continue to be developed to provide an assessment of the severity of the skin lesions. Because a lesion's impact on patients' lives varies widely among patients, there has been growing recognition of the need to measure the quality of life impact of the disease along with the severity of the lesions.

Entities:  

Mesh:

Year:  2005        PMID: 15708941      PMCID: PMC1766877          DOI: 10.1136/ard.2004.031237

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  23 in total

1.  Physical and psychologic measures are necessary to assess overall psoriasis severity.

Authors:  B Kirby; H L Richards; P Woo; E Hindle; C J Main; C E Griffiths
Journal:  J Am Acad Dermatol       Date:  2001-07       Impact factor: 11.527

2.  Psoriasis causes as much disability as other major medical diseases.

Authors:  S R Rapp; S R Feldman; M L Exum; A B Fleischer; D M Reboussin
Journal:  J Am Acad Dermatol       Date:  1999-09       Impact factor: 11.527

Review 3.  Quality of life measures in psoriasis: a critical appraisal of their quality.

Authors:  D M Ashcroft; A Li Wan Po; H C Williams; C E Griffiths
Journal:  J Clin Pharm Ther       Date:  1998-10       Impact factor: 2.512

4.  Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases.

Authors:  M M Chren; R J Lasek; S A Flocke; S J Zyzanski
Journal:  Arch Dermatol       Date:  1997-11

5.  Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire.

Authors:  J Brazier; N Jones; P Kind
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

Review 6.  Critical review of the international assessments of health-related quality of life.

Authors:  R T Anderson; N K Aaronson; D Wilkin
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

7.  The Salford Psoriasis Index: an holistic measure of psoriasis severity.

Authors:  B Kirby; D G Fortune; M Bhushan; R J Chalmers; C E Griffiths
Journal:  Br J Dermatol       Date:  2000-04       Impact factor: 9.302

Review 8.  Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality.

Authors:  D M Ashcroft; A L Wan Po; H C Williams; C E Griffiths
Journal:  Br J Dermatol       Date:  1999-08       Impact factor: 9.302

Review 9.  Psoriasis clinical registries, genetics, and genomics.

Authors:  James T Elder
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

10.  Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells.

Authors:  J G Krueger; J T Wolfe; R T Nabeya; V P Vallat; P Gilleaudeau; N S Heftler; L M Austin; A B Gottlieb
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  102 in total

1.  Sleep Quality and its Association with Disease Severity in Psoriasis.

Authors:  Mehmet Melikoglu
Journal:  Eurasian J Med       Date:  2017-06

Review 2.  Immunobiologics in the treatment of psoriasis.

Authors:  Benjamin F Chong; Henry K Wong
Journal:  Clin Immunol       Date:  2007-02-21       Impact factor: 3.969

3.  OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.

Authors:  Alexa B Kimball; Kenneth J Rothman; Gregory Kricorian; David Pariser; Paul S Yamauchi; Alan Menter; Craig F Teller; Girish Aras; Neil A Accortt; Michele Hooper; Kara Creamer Rice; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2014-09-26       Impact factor: 11.527

Review 4.  Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice.

Authors:  Aizad Mumtaz; Oliver FitzGerald
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

5.  Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM.

Authors:  Renato Goreshi; Joyce Okawa; Matt Rose; Rui Feng; Lela A Lee; Christopher B Hansen; Carolyn A Bangert; M Kari Connolly; Mark D Davis; Jeff P Callen; Nicole M Fett; Steven S Fakharzadeh; Jennie T Clarke; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

6.  Portable handheld diffuse reflectance spectroscopy system for clinical evaluation of skin: a pilot study in psoriasis patients.

Authors:  Shih-Yu Tzeng; Jean-Yan Guo; Chao-Chun Yang; Chao-Kai Hsu; Hung Ji Huang; Shih-Jie Chou; Chi-Hung Hwang; Sheng-Hao Tseng
Journal:  Biomed Opt Express       Date:  2016-01-21       Impact factor: 3.732

7.  Exploration of the Product of the 5-Point Investigator's Global Assessment and Body Surface Area (IGA × BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis.

Authors:  Alice B Gottlieb; Rebecca Germino; Vivian Herrera; Xiangyi Meng; Joseph F Merola
Journal:  Dermatology       Date:  2019-05-29       Impact factor: 5.366

8.  Doppler versus Histopathology in the Assessment of Egyptian Patients with Psoriasis Treated with Acitretin.

Authors:  Mohamed H Khater; Mohamed Soliman; Amin Amer; Fatehy Khater; Manal R Abd Elhaleem
Journal:  J Clin Aesthet Dermatol       Date:  2017-11-01

9.  Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity.

Authors:  J C Cappelleri; A G Bushmakin; J Harness; C Mamolo
Journal:  Qual Life Res       Date:  2013-03-09       Impact factor: 4.147

10.  Novel immunobiologics for psoriasis.

Authors:  Nilanjan Ghosh; P N Singh; Vikas Kumar
Journal:  Indian J Pharmacol       Date:  2008-06       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.